• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Challenges for esketamine nasal spray in China: use and management.

作者信息

Wu Jianhong, Gu Jun, Qiu Linghe, Jin Xin, Zhou Zhenhe

机构信息

The Affiliated Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, Jiangsu, China.

Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, China.

出版信息

Front Pharmacol. 2024 Oct 1;15:1429435. doi: 10.3389/fphar.2024.1429435. eCollection 2024.

DOI:10.3389/fphar.2024.1429435
PMID:39411063
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11473382/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/11473382/4c868b6c76f9/fphar-15-1429435-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/11473382/0b1a32651eac/fphar-15-1429435-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/11473382/4c868b6c76f9/fphar-15-1429435-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/11473382/0b1a32651eac/fphar-15-1429435-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b62d/11473382/4c868b6c76f9/fphar-15-1429435-g002.jpg

相似文献

1
Challenges for esketamine nasal spray in China: use and management.艾氯胺酮鼻腔喷雾剂在中国面临的挑战：使用与管理
Front Pharmacol. 2024 Oct 1;15:1429435. doi: 10.3389/fphar.2024.1429435. eCollection 2024.
2
Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance.治疗抵抗性抑郁症的实用建议：使用氯胺酮鼻喷雾剂治疗：基础科学、循证知识和专家指导。
World J Biol Psychiatry. 2021 Jul;22(6):468-482. doi: 10.1080/15622975.2020.1836399. Epub 2020 Nov 12.
3
Managing dissociative symptoms following the use of esketamine nasal spray: a case report.使用氯胺酮鼻喷雾剂后出现分离症状的管理：病例报告。
Int Clin Psychopharmacol. 2021 Jan;36(1):54-57. doi: 10.1097/YIC.0000000000000327.
4
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies.鼻内应用氯胺酮对治疗抵抗性抑郁症患者嗅觉功能和鼻腔耐受性的影响：四项多中心、随机、双盲、安慰剂对照 III 期研究的结果。
CNS Drugs. 2021 Jul;35(7):781-794. doi: 10.1007/s40263-021-00826-9. Epub 2021 Jul 7.
5
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.依他佐辛鼻喷剂联合口服抗抑郁药治疗治疗抵抗性抑郁症患者预防复发的疗效：一项随机临床试验。
JAMA Psychiatry. 2019 Sep 1;76(9):893-903. doi: 10.1001/jamapsychiatry.2019.1189.
6
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report.使用艾司氯胺酮鼻喷雾剂后味觉障碍的真实世界管理方法：一例报告。
Ann Gen Psychiatry. 2020 Feb 26;19:13. doi: 10.1186/s12991-020-00262-x. eCollection 2020.
7
Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.艾氯胺酮鼻腔喷雾剂用于治疗伴有急性自杀意念或行为的重度抑郁症：美国治疗途径、使用情况及基于索赔的结果描述
J Med Econ. 2023 Jan-Dec;26(1):691-700. doi: 10.1080/13696998.2023.2208993.
8
Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance.接受私人或公共保险覆盖的治疗抵抗性抑郁症患者中依他佐辛鼻喷雾剂的使用途径和实际使用模式。
Curr Med Res Opin. 2023 Aug;39(8):1167-1174. doi: 10.1080/03007995.2023.2239045. Epub 2023 Aug 3.
9
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.灵活剂量依他佐辛鼻喷雾剂联合新起始口服抗抑郁药治疗难治性抑郁症的疗效和安全性：一项随机、双盲、活性对照研究。
Am J Psychiatry. 2019 Jun 1;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172. Epub 2019 May 21.
10
Early Clinical Experiences of Esketamine Nasal Spray in the UK in Adults with Treatment-Resistant Major Depressive Disorder: Advisory Panel Recommendations.艾氯胺酮鼻腔喷雾剂在英国治疗难治性重度抑郁症成人患者中的早期临床经验：咨询小组建议
Neuropsychiatr Dis Treat. 2023 Feb 24;19:433-441. doi: 10.2147/NDT.S388392. eCollection 2023.

本文引用的文献

1
The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database.艾氯胺酮与特定不良事件的相关性：深入探究FAERS数据库
Eur Arch Psychiatry Clin Neurosci. 2023 Dec 16. doi: 10.1007/s00406-023-01732-5.
2
GluN2A mediates ketamine-induced rapid antidepressant-like responses.GluN2A 介导氯胺酮诱导的快速抗抑郁反应。
Nat Neurosci. 2023 Oct;26(10):1751-1761. doi: 10.1038/s41593-023-01436-y. Epub 2023 Sep 14.
3
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.
依他佐辛鼻喷雾剂治疗难治性抑郁症患者的长期安全性和疗效维持：SUSTAIN-3 研究的中期结果。
Neuropsychopharmacology. 2023 Jul;48(8):1225-1233. doi: 10.1038/s41386-023-01577-5. Epub 2023 May 12.
4
Intranasal (R, S)-ketamine delivery induces sustained antidepressant effects associated with changes in cortical balance of excitatory/inhibitory synaptic activity.经鼻给予（R，S）-氯胺酮可诱导持续的抗抑郁作用，这与皮质兴奋性/抑制性突触活动平衡的变化有关。
Neuropharmacology. 2023 Mar 1;225:109357. doi: 10.1016/j.neuropharm.2022.109357. Epub 2022 Nov 30.
5
Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System.与艾氯胺酮相关的神经系统不良事件：利用美国食品药品监督管理局不良事件报告系统进行信号检测的不成比例性分析
Front Pharmacol. 2022 Apr 8;13:849758. doi: 10.3389/fphar.2022.849758. eCollection 2022.
6
Does the Application of Deep Brain Stimulation to Modulate Memory and Neural Circuity in AD Hold Substantial Promise?应用深部脑刺激来调节阿尔茨海默病的记忆和神经回路是否具有重大前景？
Neurosci Bull. 2022 May;38(5):553-557. doi: 10.1007/s12264-021-00815-4. Epub 2022 Jan 20.
7
Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti-depressive drug on the market.依他佐辛滥用潜力的安全性问题：一种新型抗抑郁药物上市的多维分析。
Fundam Clin Pharmacol. 2022 Jun;36(3):572-581. doi: 10.1111/fcp.12745. Epub 2021 Dec 23.
8
Prevalence of depressive disorders and treatment in China: a cross-sectional epidemiological study.中国抑郁障碍的患病率及治疗状况：一项横断面流行病学研究。
Lancet Psychiatry. 2021 Nov;8(11):981-990. doi: 10.1016/S2215-0366(21)00251-0. Epub 2021 Sep 21.
9
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.总结氯胺酮和艾司氯胺酮治疗难治性抑郁症的证据：现有证据和实施情况的国际专家意见。
Am J Psychiatry. 2021 May 1;178(5):383-399. doi: 10.1176/appi.ajp.2020.20081251. Epub 2021 Mar 17.
10
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.依他佐辛上市后安全性担忧：向 FDA 不良事件报告系统自发报告提交数据的比例失调分析。
Psychother Psychosom. 2021;90(1):41-48. doi: 10.1159/000510703. Epub 2020 Aug 27.